Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple test predict Alzheimer's years before symptoms start?

NCT ID NCT00869817

Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 5 times

Summary

This long-term study follows 700 adults who carry a rare genetic mutation that causes early-onset Alzheimer's. Researchers collect blood, spinal fluid, brain scans, and cognitive tests to find biomarkers that signal the disease before memory loss begins. The goal is to improve early detection and help design future prevention trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify early warning signs of Alzheimer's in people with genetic mutations, enabling earlier diagnosis and better clinical trial design.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and findings may not apply to the more common, non-genetic forms of Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jan 2009

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Mutation carriers and non-carriers from families with a mutation (which is different from the genetic risk factor Apo-E4) known to cause Alzheimer's disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained from participant and collateral source prior to any study-related procedures. * Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD. * Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center. * Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study. * Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above. Exclusion Criteria: * Under age 18 * Medical or psychiatric illness that would interfere in completing initial and follow-up visits * Requires nursing home level care * Has no one who can serve as a study informant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Alzheimer disease 3 Alzheimer disease 4 familial Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, 1081HV, Netherlands

  • Asan Medical Center

    RECRUITING

    Seoul, Songpa-Gu, 05505, South Korea

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Butler Hospital

    RECRUITING

    Providence, Rhode Island, 02906, United States

  • Columbia University

    SUSPENDED

    New York, New York, 10032, United States

  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI)

    RECRUITING

    Salta, Salta Province, Argentina

  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa

    RECRUITING

    Buenos Aires, Argentina

  • German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich

    RECRUITING

    Munich, D-81377, Germany

  • German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen

    RECRUITING

    Tübingen, D-72076, Germany

  • Grupo Neurociencias de Antioquia

    RECRUITING

    Medellín, Colombia, Colombia

  • Hospital Clinic Barcelona

    SUSPENDED

    Barcelona, Catalonia, 08036, Spain

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo

    RECRUITING

    São Paulo, São Paulo, 05403-900, Brazil

  • Indiana University-Indiana Alzheimer Disease Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Institute of Neurology, Queen Square

    RECRUITING

    London, WC1N 3BG, United Kingdom

  • Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez"

    RECRUITING

    Mexico City, Mexico City, 14269, Mexico

  • Mayo Clinic Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • McGill University Research Centre for Studies in Aging

    NOT_YET_RECRUITING

    Verdun, Quebec, H4H 1R3, Canada

  • Mental Health Research Institute, University of Melbourne

    SUSPENDED

    Melbourne, Victoria, 3130, Australia

  • Neuroscience Research Australia

    RECRUITING

    Sydney, New South Wales, 2031, Australia

  • Niigata University

    RECRUITING

    Niigata, Japan

  • Osaka City University

    SUSPENDED

    Osaka, Japan

  • Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University

    RECRUITING

    Perth, Western Australia, 6009, Australia

  • Tokyo University

    RECRUITING

    Tokyo, Japan

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15260, United States

  • University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

  • Washington University in St. Louis School of Medicine

    RECRUITING

    St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.